Focus On Sites

By working with a range of capable sites, we can reach at-risk populations, bring interventions to those who need it most and address public health issues around the globe.


Our database of research-ready sites includes approximately 2,700 sites worldwide, with experience spanning all clinical trial phases, infectious and non-communicable diseases as well as pediatric and adult populations.

Are you a site interested in being considered for future studies with FHI Clinical?

Complete the form, and we will contact you to arrange a formal introduction with the FHI Clinical team for further evaluation of your site.


Our relationships with sites are built on our shared investment in their sustainability, helping sites develop and maintain research capacity to be able to address public health issues around the globe.
Consistent site activity through additional research opportunities
Additional financial support
Increased independence and sustainability


Each quarter, we shine the light on one of the investigators in our database as well as his or her site(s) and the research priorities in the country.
The current Site and Investigator Spotlight introduces Tariro Makadzange, MD, PhD, from the Charles River Medical Group, Pvt, Ltd (CRMG), in Harare, Zimbabwe. CMRG is listed in FHI Clinical’s database of research sites, and we look forward to working with Dr. Makadzange’s team in the future on research projects that align with their capabilities and the local epidemiology and healthcare needs.

About Dr. Makadzange

Tariro Makadzange founded CRMG and Mutala Research in late 2021, to help address the need for expertise in pandemic responsiveness and clinical trials in Africa, following more than 15 years of experience in clinical, academic and pharma roles. Her research has focused primarily on HIV immunology and implementation science as well as related opportunistic infections such as cryptococcal meningitis, in both perinatally HIV-infected children/adolescents and HIV-infected adults. She has trained and mentored clinicians and researchers in HIV and co-established the Parirenyatwa Hospital Family Care Centre (PHFCC) at the University of Zimbabwe College of Health Sciences (UZCHS), which is now one of the largest HIV treatment programs in Zimbabwe. In the pharmaceutical industry, she led a therapeutic vaccine research program at Gilead Sciences.

She earned an MD at Harvard Medical School and a PhD (DPhil) in Immunology at the University of Oxford University. She trained in Internal Medicine at the University of Washington and completed a fellowship in Infectious Diseases at Massachusetts General Hospital and Brigham and Women’s Hospital, where she later joined the faculty and formed a research partnership that resulted in the establishment of the Infectious Diseases Research Laboratory in Harare. She has also held academic positions at Harvard Medical School, Stanford University and the University of Zimbabwe.

She is a member of the Vaccine Safety and Confidence-Building Working Group at Columbia University and a board member of PSI (Population Services International). She is committed to capacity building for research in Africa and hopes to inspire young Africans to take the lead in finding scientific solutions to medical problems prevalent in Africa.

Each quarter, we shine the light on one of the investigators in our database as well as his or her site(s) and the research priorities in the country.

The current Site and Investigator Spotlight introduces Nsengi Ntamabyaliro, MD, MSc, from the Unit of Clinical Pharmacology and Pharmacovigilance (UPC-PV), University of Kinshasa, in Kinshasa, Democratic Republic of the Congo (DRC). FHI Clinical has worked with Dr. Ntamabyaliro on Phase 3 and 4 trials since 2007, at which time there was a focus on research capacity development in the DRC. Based on this history, FHI Clinical and Dr. Ntamabyaliro are currently collaborating with the UPC-PV on vaccine clinical trials and are working to identify opportunities to keep the research team active at the UPC-PV and the Kinshasa School of Public Health to sustain their research capacity.

About Dr. Ntamabyaliro

Nsengi Ntamabyaliro is a medical doctor who specialized in pharmacoepidemiology and pharmacovigilance. Since 2007 and following his clinical practice in surgery and internal medicine, Dr. Ntamabyaliro has been involved in different roles in many clinical trials: supervisor, site coordinator, co-investigator and principal investigator. His research has focused primarily on malaria but has also included trypanosomiasis, monkeypox and Ebola. Dr. Ntamabyaliro worked as a member of the pharmacovigilance team during the study of EBANGA™, one of the two drugs currently approved by the FDA for the management of Ebola virus disease.